Role of BET proteins in castration-resistant prostate cancer

Publication date: Available online 30 July 2016 Source:Drug Discovery Today: Technologies Author(s): Ester Fernandez-Salas, Shaomeng Wang, Arul M Chinnaiyan Castration resistant prostate cancer (CRPC) is a deadly disease with few therapeutic options once patients become resistant to second generation drugs targeting the AR-transcriptional program. The BET-BRD readers of chromatin are key regulators of AR-, ERG-, and c-Myc-mediated transcription in CRPC. BET-BRD inhibitors have demonstrated pre-clinical efficacy in models of CRPC and are currently being evaluated in several clinical trials. These novel drugs have the potential to transform the way we treat CRPC in the near future.
Source: Drug Discovery Today: Technologies - Category: Drugs & Pharmacology Source Type: research